RLAY

As of 2026-10-26, RLAY scores 25out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. RLAY trades at $18.12, within its fair-value band.

RLAY scores 25 out of 100 on QNTM's five-factor model — a low-conviction reading — at 25 the factor profile is among the weaker names in the universe. Its strongest factor is momentum at 50 (middling), where price trend and relative strength are working in its favor, followed by volume at 40. The weakest is value at 0, where valuation looks stretched. Among Healthcare stocks it sits in the lower 4% of Healthcare names by composite.

On valuation, RLAY is priced around the middle of its recent range. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 25. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on RLAY, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where RLAY sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for RLAY runs $12.49–$22.15. Current price $18.12 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.